Allogene Therapeutics, Inc. — Director's Dealing 2021

Feb 3, 2021

SEC Form 5 — Annual Statement of Changes in Beneficial Ownership

Issuer: Allogene Therapeutics, Inc. (ALLO)
CIK: 0001737287
Period of Report: 2020-12-31

Reporting Person: Kazam Joshua A (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-10-21	Common Stock	G	305918	—	Disposed	727387	Direct

Footnotes

F1: On October 21, 2020, the reporting person transferred 305,918 shares of common stock to an irrevocable grantor trust having an independent trustee. The reporting person disclaims beneficial ownership of these shares except to the extent, if any, of the reporting person's pecuniary interest therein.